FBXL2 counteracts Grp94 to destabilize EGFR and inhibit EGFR-driven NSCLC growth
oleh: Mengmeng Niu, Jing Xu, Yang Liu, Yuhuang Li, Tao He, Liangping Ding, Yajun He, Yong Yi, Fengtian Li, Rongtian Guo, Ya Gao, Rui Li, Luping Li, Mengyuan Fu, Qingyong Hu, Yangkun Luo, Chunyan Zhang, Kewei Qin, Jianqiao Yi, Shuhan Yu, Jian Yang, Hu Chen, Liang Wang, Zhonghan Li, Biao Dong, Shiqian Qi, Liang Ouyang, Yujun Zhang, Yang Cao, Zhi-Xiong Jim Xiao
| Format: | Article |
|---|---|
| Diterbitkan: | Nature Portfolio 2021-10-01 |
Deskripsi
Aberrant EGFR activation is commonly found in non-small cell lung cancer (NSCLC). Here the authors show that E3 ubiquitin ligase FBXL2 targets EGFR and EGFR tyrosine kinase inhibitor (TKI)-resistant mutants for proteasome-mediated degradation to inhibit EGFR-driven NSCLC growth and TKI resistance.